mdl-100907 and Parkinsonian-Disorders

Antagonising serotonin (5-HT) type 2A receptors (5-HT. Five 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmosets exhibiting dyskinesia and psychosis-like behaviours (PLBs) were administered L-3,4-dihydroxyphenylalanine (L-DOPA) in combination with vehicle or the 5-HT. EMD-281,014 reduced dyskinesia and PLBs by up to 47% and 40%, respectively (both P < 0.001). The addition of LY-354,740, LY-487,379 and LY-354,740/LY-487,379 decreased dyskinesia by 56%, 65% and 77%, while PLBs were diminished by 55%, 63% and 71% (all P < 0.001). All treatment combinations provided anti-dyskinetic and anti-psychotic benefits significantly greater than those conferred by EMD-281,014 alone (all P < 0.05). The combination of EMD-281,014/LY-354,740/LY-487,379 resulted in anti-dyskinetic and anti-psychotic effects significantly greater than those conferred by EMD-281,014 with either LY-354,740 or LY-487,379 (both P < 0.05). No deleterious effects on L-DOPA anti-parkinsonian action were observed.. Our results suggest that combining 5-HT

Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Bridged Bicyclo Compounds; Callithrix; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Parkinsonian Disorders; Piperazines; Psychotic Disorders; Pyridines; Receptors, Metabotropic Glutamate; Serotonin 5-HT2 Receptor Antagonists; Sulfonamides

The subthalamic nucleus is innervated by 5-HT afferents from the dorsal raphe nucleus and expresses high density of 5-HT(2C) receptors. However, the role of these receptors in neuronal firing of subthalamic neurons in vivo is unknown. In the present study, we examined the changes in the firing rate and firing pattern of subthalamic neurons, and the effect of the nonselective 5-HT(2C) receptor agonist m-CPP and selective antagonist SB242084 on the neuronal firing of subthalamic neurons in normal rats, sham rats, and rats with 6-hydroxydopamine lesions of the substantia nigra pars compacta by using extracellular recording. Results showed an increase in the percentage of subthalamic neurons exhibiting burst-firing pattern with no change in firing rate during the third week after the lesion compared to normal rats. The systemic administration of m-CPP (20-320 microg/kg, i.v.) dose-dependently increased the firing rate of subthalamic neurons, and the local application of m-CPP, 4 microg, in the subthalamic nucleus also increased the firing rate of subthalamic neurons in the lesioned rats. Similarly, at the same doses, the systemic and local administration of m-CPP induced the excitatory effects on subthalamic neurons in normal and sham rats. The excitatory effect of m-CPP was reversed by the subsequent administration of SB242084 (200 microg/kg, i.v.). These results suggest that the response of subthalamic neurons to 5-HT(2C) receptor stimulation is not altered after 6-hydroxydopamine lesions of the substantia nigra pars compacta.

Topics: Action Potentials; Aminopyridines; Analysis of Variance; Animals; Immunohistochemistry; Indoles; Male; Microelectrodes; Neurons; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Receptor Agonists; Substantia Nigra; Subthalamic Nucleus